Percent free prostate-specific antigen after radiotherapy for prostate cancer (Q47811165)

5 February 2018

title

Percent free prostate-specific antigen after radiotherapy for prostate cancer (English)

1 reference

5 February 2018

author name string

Crook JM

series ordinal

1

1 reference

5 February 2018

Bunting PS

series ordinal

2

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 July 1998

1 reference

5 February 2018

published in

Urology

1 reference

5 February 2018

volume

52

1 reference

5 February 2018

issue

1

1 reference

5 February 2018

page(s)

100-105

1 reference

5 February 2018

Control of prostate cancer with radiotherapy: long-term results.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Prostate-specific antigen kinetics after external beam irradiation for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

The effect of pelvic radiation therapy on serum levels of prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900119-8

7 January 2021

10.1016/S0090-4295(98)00119-8

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018